6 Surgery for Obesity and Related Diseases, vol. 3, no. 2, pp. 134– 140, 2007. [15] D. A. Winegar, B. Sherif, V. Pate, and E. J. Demaria, “Venous thromboembolism after bariatric surgery performed by Bariatric Surgery Center of Excellence Participants: analysis of the Bariatric Outcomes Longitudinal Database,” Surgery for Obesity and Related Diseases, vol. 7, no. 2, pp. 181–188, 2011. [16] G. H. Guyatt, S. L. Norris, S. Schulman et al., “Methodology for the development of antithrombotic therapy and preven- tion of thrombosis guidelines—antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines,” Chest, vol. 141, no. 2, supplement, pp. 53S–70S, 2012. [17] N. T. Nguyen, J. T. Owings, R. Gosselin et al., “Systemic coag- ulation and ﬁbrinolysis after laparoscopic and open gastric bypass,” Archives of Surgery, vol. 136, no. 8, pp. 909–916, 2001. [18] M. T. Miller and P. F. Rovito, “An approach to venous throm- boembolism prophylaxis in laparoscopic Roux-en-Y gastric bypass surgery,” Obesity Surgery, vol. 14, no. 6, pp. 731–737, 2004. [19] D. J. Scholten, R. M. Hoedema, and S. E. Scholten, “A compar- ison of two diﬀerent prophylactic dose regimens of low molec- ular weight heparin in bariatric surgery,” Obesity Surgery, vol. 12, no. 1, pp. 19–24, 2002. [20] F. Kalfarentzos, F. Stavropoulou, S. Yarmenitis et al., “Prophy- laxis of venous thromboembolism using two diﬀerent doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial,” Obesity Surgery, vol. 11, no. 6, pp. 670–676, 2001. [21] M. F. Shepherd, T. K. Rosborough, and M. L. Schwartz, “Unfractionated heparin infusion for thromboprophylaxis in highest risk gastric bypass surgery,” Obesity Surgery, vol. 14, no. 5, pp. 601–605, 2004. [22] P. Forestieri, G. Quarto, M. De Caterina et al., “Prophylaxis of thromboembolism in bariatric surgery with parnaparin,” Obesity Surgery, vol. 17, no. 12, pp. 1558–1562, 2007. [23] D. Imberti, C. Legnani, E. Baldini et al., “Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX STUDY),” Thrombosis Research, vol. 124, no. 6, pp. 667–671, 2009. [24] J. T. Paige, B. P. Gouda, V. Gaitor-Stampley et al., “No cor- relation between anti-factor Xa levels, low-molecular-weight heparin, and bleeding after gastric bypass,” Surgery for Obesity and Related Diseases, vol. 3, no. 4, pp. 469–475, 2007. [25] K. E. Steele, M. A. Schweitzer, G. Prokopowicz et al., “The long-term risk of venous thromboembolism following Bariatric surgery,” Obesity Surgery, vol. 21, no. 9, pp. 1371– 1376, 2011. [26] N. J. Gargiulo III, F. J. Veith, E. C. Lipsitz, W. D. Suggs, T. Ohki, and E. Goodman, “Experience with inferior vena cava ﬁlter placement in patients undergoing open gastric bypass procedures,” Journal of Vascular Surgery, vol. 44, no. 6, pp. 1301–1305, 2006. [27] J. B. Prystowsky, M. D. Morasch, M. K. Eskandari, E. S. Hung- ness, and A. P. Nagle, “Prospective analysis of the incidence of deep venous thrombosis in bariatric surgery patients,” Surgery, vol. 138, no. 4, pp. 759–765, 2005. [28] C. M. Trigilio-Black, C. D. Ringley, C. L. McBride et al., “Inferior vena cava ﬁlter placement for pulmonary embolism risk reduction in super morbidly obese undergoing bariatric surgery,” Surgery for Obesity and Related Diseases, vol. 3, no. 4, pp. 461–464, 2007. Thrombosis [29] F. N. Obeid, W. M. Bowling, J. S. Fike, and J. A. Durant, “Eﬃcacy of prophylactic inferior vena cava ﬁlter placement in bariatric surgery,” Surgery for Obesity and Related Diseases, vol. 3, no. 6, pp. 606–608, 2007. [30] V. R. Kakarla, K. Nandipati, M. Lalla, A. Castro, and S. Merola, “Are laparoscopic bariatric procedures safe in superobese (BMI < 50 kg/m2) patients? An NSQIP data analysis,” Surgery for Obesity and Related Diseases, vol. 7, no. 4, pp. 452–458, 2011. [31] H. Blaszyk and J. Bjo¨rnsson, “Factor V Leiden and morbid obesity in fatal postoperative pulmonary embolism,” Archives of Surgery, vol. 135, no. 12, pp. 1410–1413, 2000. [32] R. Gonzalez, K. Haines, L. G. Nelson, S. F. Gallagher, and M. M. Murr, “Predictive factors of thromboembolic events in patients undergoing Roux-en-Y gastric bypass,” Surgery for Obesity and Related Diseases, vol. 2, no. 1, pp. 30–35, 2006. [33] J. A. Sapala, M. H. Wood, M. P. Schuhknecht, and M. A. Sapala, “Fatal pulmonary embolism after bariatric operations for morbid obesity: a 24-year retrospective analysis,” Obesity Surgery, vol. 13, no. 6, pp. 819–825, 2003. [34] K. Singh, E. R. Podolsky, S. Um et al., “Evaluating the safety and eﬃcacy of bmi-based preoperative administration of low- molecular-weight heparin in morbidly obese patients under- going Roux-en-Y gastric bypass surgery,” Obesity Surgery, vol. 22, no. 1, pp. 47–51, 2012. [35] C. Stroh, D. Birk, R. Flade- Kuthe et al., “Evidence of throm- boembolism prophylaxis in Bariatric surgery-results of a quality assurance trial in Bariatric surgery in germany from 2005 to 2007 and review of the literature,” Obesity Surgery, vol. 19, no. 7, pp. 928–936, 2009. [36] A. L. Freeman, R. C. Pendleton, and M. T. Rondina, “Preven- tion of venous thromboembolism in obesity,” Expert Review of Cardiovascular Therapy, vol. 8, no. 12, pp. 1711–1721, 2010.